scispace - formally typeset
R

Riyue Bao

Researcher at University of Pittsburgh

Publications -  104
Citations -  8922

Riyue Bao is an academic researcher from University of Pittsburgh. The author has contributed to research in topics: Tumor microenvironment & Cancer. The author has an hindex of 26, co-authored 88 publications receiving 6379 citations. Previous affiliations of Riyue Bao include University of Chicago & Wayne State University.

Papers
More filters
Journal ArticleDOI

Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity

TL;DR: The mechanism by which tumour-intrinsic active β-catenin signalling results in T-cell exclusion and resistance to anti-PD-L1/anti-CTLA-4 monoclonal antibody therapy is identified, pointing to new candidate targets for immune potentiation.
Journal ArticleDOI

The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients

TL;DR: The results suggest that the commensal microbiome may have a mechanistic impact on antitumor immunity in human cancer patients and could lead to improved tumor control, augmented T cell responses, and greater efficacy of anti–PD-L1 therapy.
Journal ArticleDOI

The genome of the model beetle and pest Tribolium castaneum.

Stephen Richards, +190 more
- 24 Apr 2008 - 
TL;DR: Tribolium castaneum is a member of the most species-rich eukaryotic order, a powerful model organism for the study of generalized insect development, and an important pest of stored agricultural products.
Journal ArticleDOI

WNT/β-catenin Pathway Activation Correlates with Immune Exclusion across Human Cancers

TL;DR: Activation of tumor-intrinsic WNT/β-catenin signaling is enriched in non-T-cell-inflamed tumors, providing a strong rationale for developing pharmacologic inhibitors of this pathway with the aim of restoring immune cell infiltration and augmenting immunotherapy.
Journal ArticleDOI

Density of immunogenic antigens does not explain the presence or absence of the T-cell-inflamed tumor microenvironment in melanoma.

TL;DR: The results indicate that lack of spontaneous immune infiltration in solid tumors is unlikely to be due to lack of antigens, and strategies that improve T-cell infiltration into tumors may therefore be able to facilitate clinical response to immunotherapy once antIGens become recognized.